FANGZHOU JIANKE Holdings Limited (06086) announced on December 8, 2025, that Mr. Xie Fangmin has resigned from his positions as Chairman of the Board, Chairman and member of the Nomination Committee, Chief Executive Officer, and Authorized Representative, effective December 7, 2025, to dedicate more time to personal matters and related arrangements. The Board respects his decision and extends sincere gratitude for his outstanding leadership and invaluable contributions during his tenure. Mr. Xie has been reappointed as a Non-Executive Director and will continue to provide guidance with his extensive experience.
The Board has resolved to appoint current Non-Executive Director Mr. David McKee HAND as Chairman, effective December 7, 2025. The Nomination Committee has been tasked with initiating a formal search for a new CEO, considering both internal and external candidates to identify the most suitable successor to lead the company forward. These transitions are being carried out under the company’s robust governance framework, ensuring no disruption to existing strategies or daily operations. The Board and the new leadership team remain committed to driving steady growth.
As the founder and leader since FANGZHOU JIANKE’s establishment in 2015, Mr. Xie Fangmin has focused on long-term development and strategic expansion. He pioneered the innovative "H2H (Hospital to Home)" model and spearheaded the integration of AI with healthcare, laying a solid foundation for the company’s growth. At a critical juncture in the pharmaceutical industry’s transformation, Mr. Xie led the team in overcoming challenges, transitioning the company from an e-commerce platform to a leader in "AI + Chronic Disease Management," culminating in a successful listing on the Hong Kong Stock Exchange in 2024. His indelible contributions have earned deep respect and gratitude from the entire company.
Moving forward as a Non-Executive Director, Mr. Xie will continue leveraging his industry expertise and strategic vision to guide FANGZHOU JIANKE toward its goal of becoming "China’s Leading Smart Health Service Platform." The company remains committed to online chronic disease management, serving millions of patients through "AI + Chronic Disease Management," while building a collaborative ecosystem for chronic disease care. Aligned with the "Healthy China 2030" initiative, FANGZHOU JIANKE is poised to advance the future of intelligent healthcare with renewed momentum.
Comments